mRNA Provides Significant Long-Term Investment Opportunities

Investment Insights

The success of the mRNA-based vaccine for the COVID-19 virus established that mRNA technology is highly effective in improving the body’s immune response. Messenger ribonucleic acid (mRNA) vaccines are faster and easier to mass-produce than traditional vaccines. This feature enabled biopharma companies to invest in and produce mRNA-based COVID-19 vaccines on a large scale, which was necessary to combat the pandemic. But how does one keep fundamentals over frenzy and identify the best-placed beneficiaries? And will the capital raising activity continue to remain that strong? 

Key Takeaways:

  • The mRNA vaccine technology promises a huge growth potential to biopharma companies.
  • After the recent success of mRNA vaccines to fight against the COVID-19 virus, companies are participating in M&A and fundraising activities.
  • While mRNA is still in its infancy stage, the fight against COVID-19 has served as a significant testing ground for the technology. 
  • Companies are now exploring the possibility as well as the benefits of mRNA vaccines to treat other diseases.

To know more...


Related Topics

SG Analytics Whitepaper China Real Estate


China Real Estate : Possible Light at The End of The Tunnel

Since the inception of the three red lines policy, China's real estate sector has been heavily impacted by it, which is leading to a liquidity crunch in...

SG Analytics - IR -  China Real Estate-Easing Policy Measures Insufficient for a Sharp Turnaround


China Real Estate: Easing Policy Measures Insufficient ...

The uncertainty in China’s real estate market continues to loom on investors’ minds. With homebuyers boycotting the mortgage payments on the...

SG Analytics - Whitepaper - Buy Now, Pay Later - An Evolving Regulatory Landscape


Buy Now, Pay Later: An Evolving Regulatory Landscape

The latest buzzword in fintech, which is increasingly catching regulators’ attention worldwide, is enticingly named Buy Now, Pay Later (BNPL)....

We bring comprehensive data driven insights to everyone, everywhere